Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali

NCT02334462 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

538

Enrollment

NIH

Sponsor class

Conditions

Malaria

Interventions

BIOLOGICAL: Pfs230D1M-EPA/Alhydrogel
BIOLOGICAL: Pfs25M-EPA/Alhydrogel
DRUG: TWINRIX
DRUG: Menactra

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]